A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the S

A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open-Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis (PSC)

Obert

Codi protocol: CLIN-60190-453
Codi EudraCT: 2022-002695-37
Grup de recerca: Malalties Hepàtiques
Servei: Hepatologia
Investigador/a principal: Campos Varela, Isabel
Malaltia: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase II